Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Change in Receivables: 2009-2025

Historic Change in Receivables for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to -$81.6 million.

  • UNITED THERAPEUTICS's Change in Receivables fell 259.69% to -$81.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.1 million, marking a year-over-year decrease of 153.00%. This contributed to the annual value of $400,000 for FY2024, which is 99.32% down from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Change in Receivables stood at -$81.6 million, which was down 242.41% from $57.3 million recorded in Q2 2025.
  • UNITED THERAPEUTICS's Change in Receivables' 5-year high stood at $138.1 million during Q2 2023, with a 5-year trough of -$85.9 million in Q1 2023.
  • Over the past 3 years, UNITED THERAPEUTICS's median Change in Receivables value was $20.3 million (recorded in 2023), while the average stood at $7.0 million.
  • In the last 5 years, UNITED THERAPEUTICS's Change in Receivables slumped by 858.82% in 2021 and then surged by 4,832.14% in 2023.
  • Over the past 5 years, UNITED THERAPEUTICS's Change in Receivables (Quarterly) stood at -$14.1 million in 2021, then rose by 19.86% to -$11.3 million in 2022, then skyrocketed by 279.65% to $20.3 million in 2023, then crashed by 407.88% to -$62.5 million in 2024, then crashed by 259.69% to -$81.6 million in 2025.
  • Its Change in Receivables was -$81.6 million in Q3 2025, compared to $57.3 million in Q2 2025 and $42.7 million in Q1 2025.